CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients.

Authors: Baryshnikov, AYU  Polosukhina, ER  Tupitsin, NN  Gavrikova, NV  Andreeva, LYU  Zabotina, TN  Mayakova, SA  Kurmashov, VI  Syrkin, AB  Kadagidze, ZG  Blochin, DYU  Shishkin, YUV 
Citation: Baryshnikov AYu, etal., Adv Exp Med Biol. 1999;457:251-8.
Pubmed: (View Article at PubMed) PMID:10500800

We analyzed CD95(Fas/APO-1) antigen expression on bone marrow blasts in 38 children with acute lymphoblastic leukemia (ALL) receiving a treatment in the Department of Leukaemias at the Cancer Research Center in 1987-1989 years (n = 22) and in 1994-1997 years (n = 16). CD95 antigen expression was studied by monoclonal antibodies (MoAbs) IPO-4 in indirect immunofluorescence analysis. CD95 antigen was expressed on 35.8 +/- 7.5% bone marrow blasts, most frequently (63.6%) in the clinically favourable Pre-B ALL. Only in this group CD95 antigen expression was correlated with CD10 antigen expression that has a positive influence to the time of complete remission in ALL patients. Our data showed that CD95 expression on blast cells is a favourable prognostic sign, associated with increased relapse-free and total survival. On the contrary, the absence of CD95 antigen on blasts is an unfavourable sign for disease evolution.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11049148
Created: 2016-04-05
Species: All species
Last Modified: 2016-04-05
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.